ospective investors are
cautioned not to place undue reliance on these forward-looking statements,
which speak only as of today's date. MiddleBrook undertakes no obligation
to update or revise the information in this announcement, whether as a
result of new information, future events or circumstances or otherwise.
MIDDLEBROOK PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
Three Months Ended Twelve Months Ended
December 31, December 31,
2007 2006 2007 2006
Product sales $2,858,573 $1,243,847 $10,456,700 $4,810,410
Costs and expenses:
Cost of product
sales 712,311 381,836 2,576,954 899,601
Research and
development 3,472,544 6,273,581 21,957,708 25,973,844
Selling, general
and
administrative 5,569,764 8,287,656 26,043,711 21,288,968
Total expenses 9,754,619 14,943,073 50,578,373 48,162,413
Loss from
operations (6,896,046) (13,699,226) (40,121,673) (43,352,003)
Interest income 61,587 147,764 543,442 895,685
Interest expense (55,352) (218,633) (584,276) (510,651)
Early extinguishment
of debt (224,048) - (224,048) -
Warrant expense (2,100,000) - (2,100,000) -
Other income - - 75,000 976,815
Loss including
noncontrolling
interest (9,213,859) (13,770,095) (42,411,555) (41,990,154)
Loss attributable
to noncontrolling
interest 162,189
'/>"/>
SOURCE MiddleBrook Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Related biology technology :1.
MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million2.
MiddleBrook Pharmaceuticals to Present at BIO CEO & Investor Conference 20083.
MiddleBrook Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on March 4, 20084.
Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes5.
China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results6.
Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML7.
XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 20078.
Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results9.
Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences10.
Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer11.
Poniard Pharmaceuticals Announces Participation in Upcoming Conferences